Phage display for the generation of antibodies for proteome research, diagnostics and therapy
- PMID: 21221060
- PMCID: PMC6259421
- DOI: 10.3390/molecules16010412
Phage display for the generation of antibodies for proteome research, diagnostics and therapy
Abstract
Twenty years after its development, antibody phage display using filamentous bacteriophage represents the most successful in vitro antibody selection technology. Initially, its development was encouraged by the unique possibility of directly generating recombinant human antibodies for therapy. Today, antibody phage display has been developed as a robust technology offering great potential for automation. Generation of monospecific binders provides a valuable tool for proteome research, leading to highly enhanced throughput and reduced costs. This review presents the phage display technology, application areas of antibodies in research, diagnostics and therapy and the use of antibody phage display for these applications.
Figures
Similar articles
-
Phage display antibodies for diagnostic applications.Biologicals. 2013 Jul;41(4):209-16. doi: 10.1016/j.biologicals.2013.04.001. Epub 2013 May 3. Biologicals. 2013. PMID: 23647952 Review.
-
Phage display technology: clinical applications and recent innovations.Clin Biochem. 2002 Sep;35(6):425-45. doi: 10.1016/s0009-9120(02)00343-0. Clin Biochem. 2002. PMID: 12413604 Review.
-
Considerations on antibody-phage display methodology.Comb Chem High Throughput Screen. 2005 Mar;8(2):117-26. doi: 10.2174/1386207053258532. Comb Chem High Throughput Screen. 2005. PMID: 15777175 Review.
-
Therapeutic Antibodies by Phage Display.Curr Pharm Des. 2016;22(43):6538-6559. doi: 10.2174/1381612822666160923113714. Curr Pharm Des. 2016. PMID: 27669967 Review.
-
Current advances in antibody-based serum biomarker studies: From protein microarray to phage display.Proteomics Clin Appl. 2022 Nov;16(6):e2100098. doi: 10.1002/prca.202100098. Epub 2022 Sep 27. Proteomics Clin Appl. 2022. PMID: 36071670 Review.
Cited by
-
Neutralizing anti-diphtheria toxin scFv produced by phage display.Biotechnol Lett. 2024 Jun;46(3):385-398. doi: 10.1007/s10529-024-03476-1. Epub 2024 Apr 12. Biotechnol Lett. 2024. PMID: 38607601
-
Phage Display Derived Monoclonal Antibodies: From Bench to Bedside.Front Immunol. 2020 Aug 28;11:1986. doi: 10.3389/fimmu.2020.01986. eCollection 2020. Front Immunol. 2020. PMID: 32983137 Free PMC article. Review.
-
Bacteriophage-based bioassays: an expected paradigm shift in microbial diagnostics.Future Microbiol. 2024 Jun 12;19(9):811-824. doi: 10.2217/fmb-2023-0246. Epub 2024 Jun 20. Future Microbiol. 2024. PMID: 38900594 Free PMC article. Review.
-
Antagonist anti-LIF antibody derived from naive human scFv phage library inhibited tumor growth in mice.BMC Immunol. 2024 Aug 22;25(1):56. doi: 10.1186/s12865-024-00636-w. BMC Immunol. 2024. PMID: 39169307 Free PMC article.
-
Application of M13 phage display for identifying immunogenic proteins from tick (Ixodes scapularis) saliva.BMC Biotechnol. 2015 May 30;15:43. doi: 10.1186/s12896-015-0167-3. BMC Biotechnol. 2015. PMID: 26024663 Free PMC article.
References
-
- Köhler G., Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 1975;256:495–497. - PubMed
-
- Courtenay-Luck N.S., Epenetos A.A., Moore R., Larche M., Pectasides D., Dhokia B., Ritter M.A. Development of primary and secondary immune responses to mouse monoclonal antibodies used in the diagnosis and therapy of malignant neoplasms. Cancer Res. 1986;46:6489–6493. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
